Published by Josh White on 25th October 2022
(Sharecast News) - Immunotherapy developer Scancell announced a licensing agreement with the Nasdaq-listed Genmab on Tuesday, to develop and commercialise a Scancell investigational anti-glycan monoclonal antibody into novel therapeutic products.
URL: http://www.digitallook.com/dl/news/story/33059571/...